Bryostatin 1
- Generic Name
- Bryostatin 1
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C47H68O17
- CAS Number
- 83314-01-6
- Unique Ingredient Identifier
- 37O2X55Y9E
- Background
Bryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
Phase 1
Completed
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous LeukemiaChronic Myelomonocytic LeukemiaChronic Phase Chronic Myelogenous Leukemia
- Interventions
- Drug: bryostatin 1Biological: sargramostimOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00012376
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
Phase 2
Completed
- Conditions
- Stage IV Gastric CancerStage III Gastric Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00006389
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
Phase 2
Completed
- Conditions
- Duct Cell Adenocarcinoma of the PancreasStage IV Pancreatic CancerAcinar Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage III Pancreatic Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00031694
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath